New York, New York, October 10, 2024 – PRISM MediaWire – PRISM MediaWire – Mental health has not always been a topic to discuss as easily as other health related topics due to the stigma surrounding it. Those who have identified having a mental health condition typically do not seek the proper help or treatment for fear of judgement or admission to being unstable. The reality of it is that whether or not you have a condition, we all need to do things to ensure we have good mental health in the same manner we do physically. In the same way we eat healthy to help us from getting sick, we should take each day to do something that helps us relieve the stress or emotions that might be placing a burden on our mental wellbeing. Some ways that can help are journaling, talking to someone, or taking a walk.
Today, October 10th is World Mental Health Day and is intended to raise global awareness of mental health issues and to inspire efforts to support mental health. It offers a platform for stakeholders involved in mental health to share their work and discuss what more can be done to ensure access to mental health care for everyone, everywhere.
PRISM has examined the Mental Health Index and has highlighted some companies who are focused on addressing various conditions that can affect mental health and discusses their focus and recent news as they work to make a difference for those struggling.
Brainsway Ltd. (BWAY) is a global medical technology company specializing in the development and commercialization of advanced non-invasive treatments for mental health and neurological disorders. The company’s primary product is its Deep Transcranial Magnetic Stimulation (Deep TMS) system, which uses magnetic fields to stimulate specific brain regions. This technology is FDA-cleared and CE-marked for the treatment of conditions like depression, obsessive-compulsive disorder (OCD), and smoking addiction. Brainsway operates in over 60 countries, providing innovative solutions for patients who have not responded to traditional therapies. In recent news, the company announced it intends to further penetrate East Asia with placement of 15 additional Deep TMS Systems in Taiwan and South Korea. Brainsway also has secured $20M private placement with Valor Equity Partners that sent shares up 12% on the announcement.
Sage Therapeutics Inc. (SAGE) is a biopharmaceutical company focused on developing novel therapies for brain health disorders, including depression and neuropsychiatric conditions. The company’s primary focus is on discovering and commercializing treatments that target the central nervous system (CNS), with a portfolio that includes products for major depressive disorder (MDD), postpartum depression (PPD), and other mental health conditions. Sage Therapeutics utilizes its expertise in neurobiology to develop new medications aimed at improving patient outcomes, particularly for those who have not responded to existing treatments. The company is based in the U.S. and operates in the global healthcare market. Recently, the company announced topline results from its Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the treatment of mild cognitive impairment and mild dementia in Alzheimer’s Disease which reported it to be well tolerated with no safety signals observed.
Vistagen Therapeutics Inc. (VTGN) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system (CNS) disorders. The company focuses on transforming the treatment landscape for mental health conditions such as anxiety, depression, and other mood disorders through its novel drug candidates. Vistagen’s pipeline includes nasal spray therapies and other non-invasive treatments designed to address unmet medical needs, particularly in conditions where current treatment options are limited or ineffective. With a strong emphasis on safety and patient well-being, Vistagen aims to bring transformative mental health solutions to the global market. Today, Vistagen will be ringing the Nasdaq closing bell in honor of World Mental Health Day. Additionally, the company has recently initiated its PALISADE-4 Phase 3 Study of Fasedienol for the acute treatment of Social Anxiety Disorder.
Bionomics Limited (BNOX) is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for central nervous system (CNS) disorders, including anxiety, depression, and cognitive impairment. The company leverages its expertise in ion channel biology and neuropharmacology to develop novel small molecule drug candidates aimed at addressing unmet medical needs in neurological and psychiatric conditions. Bionomics’ lead programs target conditions like PTSD and anxiety disorders, with a goal of delivering effective treatments for patients who have not benefited from traditional therapies. The company operates globally and is based in Australia. Most recently the company issued a shareholder letter highlighting recent achievements and its strategic vision. Prior to that Bionomics also reported its successful End-of-Phase 2 meeting with the FDA on the development of BNC210 in Post-Traumatic Stress Disorder.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Contact:
PRISM MarketView
info@prismmarketview.com
646-863-6341
Source: PRISM MarketView